Edwards Lifesciences Corp (EW)vsLucid Diagnostics Inc (LUCD)
EW
Edwards Lifesciences Corp
$85.96
-1.70%
HEALTHCARE · Cap: $49.01B
LUCD
Lucid Diagnostics Inc
$1.01
-2.43%
HEALTHCARE · Cap: $187.53M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 122680% more annual revenue ($6.30B vs $5.13M). EW leads profitability with a 17.4% profit margin vs 0.0%. EW earns a higher WallStSmart Score of 61/100 (C+).
EW
Buy61
out of 100
Grade: C+
LUCD
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.7%
Fair Value
$253.29
Current Price
$85.96
$167.33 discount
Intrinsic value data unavailable for LUCD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
16.7% revenue growth
Revenue surging 51.7% year-over-year
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -711.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bull Case : LUCD
The strongest argument for LUCD centers on Revenue Growth. Revenue growth of 51.7% demonstrates continued momentum.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.
Bear Case : LUCD
The primary concerns for LUCD are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 6.70 is elevated, increasing financial risk.
Key Dynamics to Monitor
EW profiles as a growth stock while LUCD is a hypergrowth play — different risk/reward profiles.
LUCD carries more volatility with a beta of 1.08 — expect wider price swings.
LUCD is growing revenue faster at 51.7% — sustainability is the question.
LUCD generates stronger free cash flow (-12M), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 29/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Lucid Diagnostics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Lucid Diagnostics Inc. is a commercial stage medical diagnostic technology company. The company is headquartered in New York, New York.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?